Search
BF-1
go.drugbank.com/drugs/DB06029ExperimentalBF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.
SL017
go.drugbank.com/drugs/DB05156ExperimentalSL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Tetrodotoxin
go.drugbank.com/drugs/DB05232InvestigationalAn aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction. Tetrodotox...
Peptide YY (3-36)
go.drugbank.com/drugs/DB05004InvestigationalPeptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
SN-38
go.drugbank.com/drugs/DB05482Investigational7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studyin...
AME-527
go.drugbank.com/drugs/DB05879ExperimentalAME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its impr...
Repinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Azimilide
go.drugbank.com/drugs/DB04957InvestigationalAzimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in th...
BTA9881
go.drugbank.com/drugs/DB05226InvestigationalBTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.